Loading viewer...
conference
Format: PDF conference
Aethlon Medical presented its immunotherapeutic platform focused on cancer and infectious disease treatment at the LD Micro Invitational XIII Conference. The company highlighted its first-in-class Hemopurifier device, which has demonstrated exosome and circulating virus capture in clinical trials and received FDA Breakthrough Device designation for two indications. Aethlon maintains a solid financial position with no debt and is advancing clinical development of its lead therapeutic technology.
presentation
conference
27 Pages
Guidance Software
Ryerson Holding 2023 J.P. Morgan Industrials Conference
conferenceconference
64 Pages
Ryerson Holding Corporation